Twelve Months or Faster Access: What Europe Asks in Return for Public Money in Biotech
The European Biotech Act hands out a twelve-month extension of exclusivity and asks where you manufacture. Spain proposes buying access instead. Two instruments, one objective, entirely different obligations.
